Royal Canin

Royal Canin is a premium pet food company producing highly specialized, veterinary-aligned nutrition for cats and dogs — offering breed-specific formulas, life stage formulas, and therapeutic veterinary diets prescribed by veterinarians for pets with health conditions including kidney disease, urinary issues, diabetes, and joint problems. Founded in 1968 by French veterinarian Jean Cathary in the Gard region of France, Royal Canin is owned by Mars, Inc. (the private confectionery and pet care conglomerate, which acquired Royal Canin in 2001), generating approximately €4 billion in annual sales as one of the top premium pet food brands globally.\n\nRoyal Canin's product differentiation is its science-based nutrition philosophy and breed-specific formulations — the company produces dozens of formulas tailored to the specific physiological needs of individual dog and cat breeds (the Yorkshire Terrier formula addresses the breed's jaw anatomy and coat maintenance needs, the Persian cat formula has a modified kibble shape for flat-faced brachycephalic cats). Veterinary diets (sold through veterinary clinics and prescription channels) address medical conditions with therapeutic nutrition — a segment with significant pricing power and vet channel distribution loyalty.\n\nIn 2025, Royal Canin operates within Mars Petcare alongside Pedigree, Whiskas, and Iams, competing with Hill's Pet Nutrition (Colgate-Palmolive), Purina Pro Plan (Nestlé), and premium pet food brands for veterinary and specialty pet retail distribution. The premium pet food market has grown substantially as pet humanization trends drive spending on premium nutrition. Royal Canin's 2025 strategy focuses on expanding its veterinary relationship (the vet recommendation channel remains critical for therapeutic and puppy/kitten starter nutrition), growing its personalized nutrition capabilities, and expanding in Asia Pacific markets where pet ownership is growing rapidly.